Safety of menopausal hormone therapy in breast cancer survivors older than fifty at diagnosis: A systematic review and meta-analysis.


Journal

Breast (Edinburgh, Scotland)
ISSN: 1532-3080
Titre abrégé: Breast
Pays: Netherlands
ID NLM: 9213011

Informations de publication

Date de publication:
Oct 2019
Historique:
received: 27 01 2019
revised: 02 06 2019
accepted: 07 06 2019
pubmed: 26 7 2019
medline: 6 2 2020
entrez: 26 7 2019
Statut: ppublish

Résumé

Due to the higher incidence of hormone responsive tumours in women >50, the safety of hormone replacement therapy (HRT) in older breast cancer survivors may differ from younger age groups. The primary outcome in this review was the risk of tumour recurrence and secondary outcome the relationship with breast cancer-related mortality. Medline, CINAHL, Cochrane, Google Scholar and EMBASE databases were searched through August 2018 for studies reporting exposure to HRT in survivors ≥50 at primary diagnosis. Random effects models were used to estimate the combined relative risk (RR) of tumour recurrence and breast cancer-related mortality using the Mantel-Haenszel method and the quality of evidence determined for the primary outcome. Overall, nine studies (four cohort, one case-control, four RCTs; n = 16,002) were included. Very low quality evidence from observational studies demonstrated no adverse effect on tumour recurrence with HRT use (RR 0.80, 95% CI 0.53 to 1.19; I

Identifiants

pubmed: 31344603
pii: S0960-9776(19)30514-4
doi: 10.1016/j.breast.2019.06.002
pii:
doi:

Types de publication

Journal Article Meta-Analysis Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

43-55

Informations de copyright

Copyright © 2019 Elsevier Ltd. All rights reserved.

Auteurs

Godfrey H Mudhune (GH)

Translational Health Research Institute, Western Sydney University, Penrith, NSW, 2750, Australia.

Mike Armour (M)

Translational Health Research Institute, Western Sydney University, Penrith, NSW, 2750, Australia; NICM Health Research Institute, Western Sydney University, Penrith, NSW, 2751, Australia.

Kate A McBride (KA)

Translational Health Research Institute, Western Sydney University, Penrith, NSW, 2750, Australia; School of Medicine, Western Sydney University, Penrith, NSW, 2750, Australia. Electronic address: K.McBride@westernsydney.edu.au.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH